Morgan Stanley raised UnitedHealth's price target to $453 from $395, with BofA and Truist increasing theirs to $450 and $440 respectively, reflecting improving Q1 medical cost trends and a favorable Q2 outlook. Shares surged over 5% as analysts noted moderating utilization and potential AI-driven efficiencies delivering 45% EPS upside.
Morgan Stanley raised its UnitedHealth price target from $395 to $453, while BofA bumped its target to $450 and Truist lifted theirs to $440, signaling strong analyst conviction in the stock’s upside potential.
First-quarter medical cost trends came in below consensus expectations, driven by moderating utilization and lower acute care expenses, setting the stage for a favorable second-quarter earnings environment.
Analysts highlighted emerging AI-driven efficiencies across revenue and cost levers, estimating these capabilities could deliver roughly 45% average EPS upside as they scale within managed care operations.
Following the string of upgrades and raised targets, UnitedHealth shares jumped over 5% in a single trading session, reflecting heightened investor enthusiasm around cost management and technology-driven growth.
